1380084-83-2

Basic information

• Product Name: (2-{5-[3-(4-methanesulfonylamino-phenyl)-propylidene]-2,4-dioxo-thiazolidin-3-yl}-ethyl)-carbamic acid tert-butyl ester
• Synonyms: (2-{5-[3-(4-methanesulfonylamino-phenyl)-propylidene]-2,4-dioxo-thiazolidin-3-yl}-ethyl)-carbamic acid tert-butyl ester
• CAS NO: 1380084-83-2
• Molecular Weight: 469.583
• Mol File: 1380084-83-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2-{5-[3-(4-methanesulfonylamino-phenyl)-propylidene]-2,4-dioxo-thiazolidin-3-yl}-ethyl)-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2-{5-[3-(4-methanesulfonylamino-phenyl)-propylidene]-2,4-dioxo-thiazolidin-3-yl}-ethyl)-carbamic acid tert-butyl ester(1380084-83-2)
• EPA Substance Registry System: (2-{5-[3-(4-methanesulfonylamino-phenyl)-propylidene]-2,4-dioxo-thiazolidin-3-yl}-ethyl)-carbamic acid tert-butyl ester(1380084-83-2)

Safety Data

• Hazardous Substances Data: 1380084-83-2(Hazardous Substances Data)

Upstream product

• 540-37-4 p-aminoiodobenzene 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 1357306-22-9 C₁₀H₁₃NO₃S 
• 102294-59-7 N-(4-iodophenyl)-methanesulfonamide 

Downstream Products

• 1357306-10-5 N-(4-{3-[3-(2-aminoethyl)-2,4-dioxothiazolidin-5-ylidene]-propyl}-phenyl)methanesulfonamide 

Relevant articles and documents

3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: Design, synthesis and biological characterization

A series of 2,5-disubstituted-thiazolidine-2,4-dione analogs based on the newly identified lead 1, a potential anticancer agent via the inhibition of the Raf/MEK/extracellular signal regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascades, were synthesized and biologically characterized. A new lead structure, 15, was identified to have improved anti-proliferative activities in U937 cells, to induce apoptosis in U937, M12 and DU145 cancer cells, and to arrest U937 cells at the S-phase. Furthermore, Western blot analysis demonstrated a correlation of the anti-proliferative activity and blockade of the Raf/MEK/ERK and PI3K/Akt signaling pathways. Collectively, these results strongly encourage further optimization of 15 as a new lead with multi-target properties to develop more potent compounds as anticancer agents.